We report a 58-years-old woman, whose right thyroid neoplasms were diagnosed as papillary thyroid carcinoma...The tumor showed no response to sorafenib....next generation sequencing (NGS)...showed BRAF V600E mutation and TERT promoter mutation...she then received combination therapy with dabrafenib, 150 mg twice daily, and trametinib, 2 mg daily. After 5 months of dabrafenib and trametinib treatment, the tumor was significantly reduced. After that, the disease progressed rapidly, and transformed to anaplastic carcinoma.